Evofem Biosciences

Evofem Biosciences is a U.S.-based biopharmaceutical company founded in 2009, dedicated to developing and commercializing innovative products for women's sexual and reproductive health. The company's slogan - "Developing and commercializing products that address unmet needs in women’s sexual and reproductive health" encapsulates its core mission. In September 2020, Evofem achieved a significant milestone by launching Phexxi, the first and only hormone-free, on-demand, prescription birth control available in the U.S. designed for use only when needed. This development marks a pioneering step in providing women with more personalized and convenient contraceptive options. Evofem has attracted a $1.00M Post-IPO Equity investment at 15 May 2024, with the investment coming from Aditxt Therapeutics. This demonstrates the confidence that other players in the industry have in Evofem's vision and product potential. Evofem's activities sit at the intersection of the Biopharma and Health Care industries, reflecting its commitment to advancing healthcare and empowering women.